These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 26038989)

  • 41. Is treatment failure for hepatitis C virus infection in HIV-positive drug users associated with a shift in HCV genotypes?
    Soriano V; Pérez-Olmeda M; Ríos P; Núñez M; García-Samaniego J; González-Lahoz J
    J Acquir Immune Defic Syndr; 2003 Apr; 32(4):465-6. PubMed ID: 12640209
    [No Abstract]   [Full Text] [Related]  

  • 42. Hepatitis C recurrence in liver transplant recipients.
    Kizilisik TA; al-Sebayel M; Hammad A; al-Traif I; Ramirez CG; Abdulla A
    Transplant Proc; 1997 Nov; 29(7):2875-7. PubMed ID: 9365599
    [No Abstract]   [Full Text] [Related]  

  • 43. [Hepatitis C in childhood--natural history and therapy].
    Nagata I; Murakami J; Okamoto M; Iitsuka T; Kanzaki S; Shiraki K
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):634-9. PubMed ID: 15359875
    [No Abstract]   [Full Text] [Related]  

  • 44. Prisoners treated for hepatitis C with protease inhibitor, New York, USA, 2012.
    Moorjani H; Koenigsmann C; Kim MJ; Spaulding AC
    Emerg Infect Dis; 2015 Jan; 21(1):186-8. PubMed ID: 25531029
    [No Abstract]   [Full Text] [Related]  

  • 45. [Multicenter study on the inhibition of hepatocarcinogenesis by interferon therapy (IHIT)].
    Yoshida H; Omata M
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):463-6. PubMed ID: 15359842
    [No Abstract]   [Full Text] [Related]  

  • 46. Management of hepatitis C virus coinfection in HIV-infected persons.
    O'Leary JG; Chung RT
    AIDS Read; 2006 Jun; 16(6):313-6, 318-20. PubMed ID: 16795921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. New therapeutic strategies for hepatitis C.
    Di Bisceglie AM; McHutchison J; Rice CM
    Hepatology; 2002 Jan; 35(1):224-31. PubMed ID: 11786980
    [No Abstract]   [Full Text] [Related]  

  • 48. Outcomes and costs of care in hepatitis C: combination therapy scores again.
    Koff RS
    Am J Gastroenterol; 2000 Jun; 95(6):1392-3. PubMed ID: 10894568
    [No Abstract]   [Full Text] [Related]  

  • 49. [Hepatitis C is curable. Even slightly elevated liver enzymes need further examination].
    Niederau C
    MMW Fortschr Med; 2008 Mar; 150(13):26. PubMed ID: 18522352
    [No Abstract]   [Full Text] [Related]  

  • 50. [New drugs for hepatitis C].
    Färkkilä M
    Duodecim; 2014; 130(18):1813-22. PubMed ID: 25558623
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The science, economics, and effectiveness of combination therapy for hepatitis C.
    Dusheiko G; Barnes E; Webster G; Whalley S
    Gut; 2000 Aug; 47(2):159-61. PubMed ID: 10896900
    [No Abstract]   [Full Text] [Related]  

  • 52. [The recurrence of hepatitis C virus after liver transplantation].
    Nemes B; Sárváry E; Gerlei Z; Fazakas J; Doros A; Németh A; Görög D; Fehérvári I; Máthé Z; Gálffy Z; Pár A; Schuller J; Telegdy L; Fehér J; Lotz G; Schaff Z; Nagy P; Járay J; Lengyel G
    Orv Hetil; 2007 Oct; 148(42):1971-9. PubMed ID: 17932003
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Hepatitis C virus therapies.
    Smith RE
    Nat Rev Drug Discov; 2006 Sep; 5(9):715-6. PubMed ID: 17001802
    [No Abstract]   [Full Text] [Related]  

  • 54. Recovery from chronic hepatitis C in long-term responders to ribavirin plus interferon alfa.
    Fontaine H; Chaix ML; Lagneau JL; Bréchot C; Pol S
    Lancet; 2000 Jul; 356(9223):41. PubMed ID: 10892765
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Should treatment of hepatitis C in HIV-seropositive and HIV-seronegative patients with hemophilia include induction doses of interferon?
    McGovern B; Bica I
    Clin Infect Dis; 2003 Aug; 37(3):463-4; author reply 464-5. PubMed ID: 12884180
    [No Abstract]   [Full Text] [Related]  

  • 56. [Screening, diagnosis, treatment, and follow up of hepatitis C virus related liver disease. National consensus guideline in Hungary from 15 October 2016].
    Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Péter Z; Rókusz L; Schneider F; Szalay F; Tornai I; Werling K; Makara M
    Orv Hetil; 2017 Feb; 158(Suppl 1):3-22. PubMed ID: 28218867
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hepatitis C: current and future therapies.
    Mishra P; Jensen DM
    Mt Sinai J Med; 2008 Aug; 75(4):405-14. PubMed ID: 18729159
    [No Abstract]   [Full Text] [Related]  

  • 58. [When and how should hepatitis C be treated?].
    Färkkilä M
    Duodecim; 2010; 126(1):41-8. PubMed ID: 20405608
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Treatment of hepatitis C: a decision that needs careful consideration.
    Wright TL
    Am J Med; 1999 Aug; 107(2):180-1. PubMed ID: 10460052
    [No Abstract]   [Full Text] [Related]  

  • 60. Comparative Clinical Effectiveness and Value of Novel Interferon-Free Combination Therapy for Hepatitis C Genotype 1: Summary of California Technology Assessment Forum Report.
    Tice JA; Chahal HS; Ollendorf DA
    JAMA Intern Med; 2015 Sep; 175(9):1559-60. PubMed ID: 26167717
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.